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Abstract
Primary T-cell activation at mucosal sites is of utmost importance for the development of vaccination strategies. T-cell
priming after vaginal immunization, with ovalbumin and CpG oligodeoxynucleotide adjuvant as model vaccine formulation,
was studied in vivo in hormone-synchronized mice and compared to the one induced by the nasal route. Twenty-four hours
after both vaginal or nasal immunization, antigen-loaded dendritic cells were detected within the respective draining lymph
nodes. Vaginal immunization elicited a strong recruitment of antigen-specific CD4+ T cells into draining lymph nodes that
was more rapid than the one observed following nasal immunization. T-cell clonal expansion was first detected in iliac
lymph nodes, draining the genital tract, and proliferated T cells disseminated towards distal lymph nodes and spleen
similarly to what observed following nasal immunization. T cells were indeed activated by the antigen encounter and
acquired homing molecules essential to disseminate towards distal lymphoid organs as confirmed by the modulation of
CD45RB, CD69, CD44 and CD62L marker expression. A multi-type Galton Watson branching process, previously used for in
vitro analysis of T-cell proliferation, was applied to model in vivo CFSE proliferation data in draining lymph nodes 57 hours
following immunization, in order to calculate the probabilistic decision of a cell to enter in division, rest in quiescence or
migrate/die. The modelling analysis indicated that the probability of a cell to proliferate was higher following vaginal than
nasal immunization. All together these data show that vaginal immunization, despite the absence of an organized mucosal
associated inductive site in the genital tract, is very efficient in priming antigen-specific CD4+ T cells and inducing their
dissemination from draining lymph nodes towards distal lymphoid organs.
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Introduction
T-cell priming at mucosal sites is of primary importance for the
development of mucosal vaccine formulations and prime-boost
strategies aimed to elicit mucosal and systemic effector immune
responses. Despite the many attractive features of mucosal
vaccination, only few vaccines approved for human use are
currently administered mucosally, and they are all based on live
attenuated microorganisms with none on subunit of pathogens [1–
4]. To advance the development of new mucosal vaccines, not
only appropriate antigens, adjuvants and delivery systems but also
proper mucosal routes of administration should be deeply
characterised [1,5–7].
The induction of mucosal immune responses requires the
presence of a mucosa-associated lymphoid tissue that provides a
continuous source of B and T cells to mucosal effector sites [8].
Inductive sites for mucosal immunity consist of organized mucosa-
associated lymphoid tissue as well as local and regional draining
lymph nodes (LNs), whereas the effector sites include distinctly
different histological compartments, mainly consisting of the
lamina propria of various mucosae [9]. Inductive sites in the
gastro-intestinal and respiratory tracts have been well defined and
are composed by aggregated lymphoid tissues (gut-, nasal- and
bronchial-associated lymphoid tissues respectively) and mucosa-
associated lymph nodes (mesenteric and mediastinal lymph nodes),
on the contrary the vaginal mucosa is devoid of histologically
demonstrable organised mucosa-associated lymphoid tissue and
the role of inductive site is played directly by draining iliac lymph
nodes [5].
Female genital tract has therefore some unique features that
should be taken in consideration in the development of
vaccination strategies. Following vaginal immunization T-cell
priming occurs in the iliac lymph nodes from which T and B cells
migrate to the effector sites [5,6,10–12]. Antigens are sampled
from the vaginal lumen by macrophages and dendritic cells (DCs)
that then move towards draining iliac lymph nodes. Antigen-
uptake across the vaginal mucosa barrier and immune responses in
the genital tract are greatly regulated and influenced by the
hormonal state and estrus phase [13–16]. Sex hormones also affect
the migration of macrophages and DCs as well as T and B cells by
involving the expression of adhesion molecules and chemotactic
factors [17]. In particular, there are indications that estradiol,
which induces an estrus-like state, inhibits T-cell priming
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preventing antigen loading by vaginal antigen presenting cells
(APCs) after vaginal immunization, while progesterone, inducing a
diestrous phase, facilitates antigen-uptake and T-cell activation
[18,19]. Hormonally mediated variations through the estrous cycle
act also on the mucosal cell number and subset, having important
implications in the antigen-uptake and subsequent T-cell priming
[14,19–22]. The phase of the menstrual cycle is indeed carefully
taken into consideration in clinical trials of vaginal immunization
(source www.clinicaltrials.gov).
The nasal route of vaccination targets the lymphoid tissue
associated with the nasopharynx (NALT) and is recognised as an
efficient inductive site capable of disseminating primed cells also to
distal sites [10], and stimulate an immune response also in distal
effector sites and systemically [8,10,23–28]. Previous studies
conducted in this laboratory have deeply characterised the
antigen-specific T-cell priming following nasal immunisation
[29–32].
To overcome the limitation of the very low number of antigen-
specific T cells in vivo [33], we have employed the adoptive transfer
system of antigen-specific transgenic T cells into immunocompe-
tent mice [34,35]. By using this method, we have characterized T-
cell clonal expansion and dissemination following nasal immuni-
zation showing that divided T cells, generated in the nasal
associated lymphoid tissues and in draining cervical and medias-
tinal lymph nodes, migrate towards distal lymphoid organs, such
as iliac and mesenteric lymph nodes and the spleen [31,35]. The
entry of nasally primed T cells into iliac lymph nodes was also
shown to be strictly CD62L-dependent, while homing to
mesenteric lymph nodes is regulated by both CD62L and a4b7
molecules [32].
For studying in vivo T-cell priming events, mathematical models
represent an attractive tool to obtain quantitative information on
the rates of division, death and migration. The application of
mathematical models can indeed be highly relevant to analyse
antigen-specific T-cell primary clonal expansion, based on the
dilution of the carboxyfluorescein diacetate succinimidyl ester
(CFSE) dye. It is well established that natural T-cell proliferation is
inherently a stochastic phenomenon [36]. In stochastic models,
cells are considered to act independently and divide or die
accordingly to probabilistic rules. The Multi-type Galton Watson
branching process is a prototypical branching process representing
the development of a population whose members reproduce and
die subject to random laws [37]. Quantitative analysis of CFSE
data through mathematical models has been previously employed
for studying in vitro, but not in vivo, cell proliferation [38–40].
Indeed, in vivo analysis raises several difficulties, mainly due to the
fact that a lymph node is not an ‘isolated’ site but is part of the
complex immunological system.
In the present work, we investigated the antigen-specific CD4+
T-cell primary activation following vaginal or nasal immunization
with the model vaccine formulation constituted by ovalbumin
(OVA) plus CpG oligodeoxynuclotide (ODN) 1826 as adjuvant.
CpG is a Toll like receptor 9 ligand, that has been extensively
described as an effective adjuvant for mucosal immunisation [41].
The distribution of OVA-bearing DCs at early time points
following immunization was analysed using a fluorescent antigen.
Primary activation and dissemination of antigen-specific T cells
was studied in vivo after adoptive transfer of OVA-specific
transgenic CD4+ T cells. Clonal expansion of transgenic T cells
was evaluated in draining and distal lymph nodes and in the spleen
at different time points. We adopted a multi-type branching
process with immigration to model T-cell proliferation in vivo and
estimated the probability of a cell to enter in division, rest in
quiescence or migrate/die following both vaginal and nasal
immunization.
Materials and Methods
Mice
Nine week old female OT-II [42] TCR-transgenic mice (H-2b)
and C57BL/6J mice were purchased from Charles River (Lecco,
Italy). Animals were maintained under specific pathogen-free
conditions in the animal facilities at the University of Siena, and
treated according to national guidelines (Decreto Legislativo
January 27, 1992 n. 116, implementing 86/609/CEE Directive).
All animal studies were approved by the Ethics Committee
‘‘Comitato Etico Locale dell’Azienda Ospedaliera Universitaria
Senese’’ and the Italian Ministry of Health (number 4/2011, July
20, 2011).
Antigen uptake by DCs
Six days before immunisation, the estrous cycle of mice was
synchronized in the diestrous phase by subcutaneous injection of
medroxyprogesterone (Depo-Provera, Pfizer, Italy) (3 mg/mouse)
or in the estrous phase by administration of ß-estradiol valerate
(Sigma–Aldrich) (0.1 mg/mouse). The stage of estrus was
confirmed by vaginal smear. OVA uptake was tracked in vivo
using ovalbumin-Alexa fluor 647 conjugate (Invitrogen Molecular
Probes, Eugene, OR, USA). C57BL/6J mice were lightly
anaesthetized by intraperitoneal injection of tiletamine, zolazepam
hydrochloride (Zoletil 20, Laboratoires Virbac, France, 6 mg/kg)
and xylazine (Xilor 2%, Bio 98 Srl, Italy, 3 mg/kg), and
immunised by vaginal or nasal route with the fluorescent OVA
(25 mg/mouse) mixed with the mucosal adjuvant CpG ODN 1826
(TCC ATG ACG TTC CTG ACG TT, Eurofins MWG Operon,
Ebersberg, Germany) (20 mg/mouse). Mice immunized by vaginal
route were housed in single cages and equipped with a collar for
some hours to avoid self sniffing.
Groups of four animals were sacrificed 12, 24 and 72 hours
after mucosal immunization. Iliac (subiliac, medial and external),
cervical (superficial and posterior) lymph nodes and spleen were
harvested and digested in Click’s medium (Sigma-Aldrich) with
2 mg/ml of Collagenase D (Roche Applied Science, Penzberg,
Germany) for 30 min at 37uC. Organs were mashed onto nylon
screens (Sefar Italia, Italy) and washed in PBS with 0.5% of bovine
serum albumin (BSA, Sigma-Aldrich) and 2 mM EDTA (Mal-
linckrodt Baker, Philipsburg, NJ, USA).
Adoptive transfer of transgenic CD4+ T cells
Single cell suspensions from the spleen and pooled lymph nodes
(cervical, brachial, axillary, mesenteric and iliac) of OT-II
transgenic mice were enriched for CD4+ T cells, by negative
selection using the EasySep magnetic nanoparticles (StemCell
Technologies, Vancouver, BC, Canada), according to the
manufacturer’s protocol. The purity of the CD4+ T-cell popula-
tion in the enriched fraction was .95%, as determined by flow
cytometric analysis. OT-II transgenic CD4+ T cells were stained
with CFSE (7.5 mM, Invitrogen) [43], for 10 min at 37uC. An
amount of 2.56106 of CFSE-labelled T cells were injected into the
tail vein of each recipient mouse.
Vaginal and nasal immunization of mice and sample
collection
Twenty-four hours after adoptive transfer of CFSE-labelled
OT-II CD4+ T cells, progesterone treated C57BL/6J mice were
vaginally or nasally immunized with OVA grade V (Sigma-
Aldrich) (25 mg/mouse) and CpG ODN 1826 (20 mg/mouse).
T-Cell Priming following Vaginal Immunization
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Mice were lightly anaesthetized by intraperitoneal injection and
then inoculated with OVA and CpG into the vagina or into
nostrils with a volume of 15 ml. Mice immunized by vaginal route
were housed individually and equipped with a collar for some
hours to avoid self sniffing.
Groups of six mice were sacrificed 0, 48, 57, 72, 120 and
168 hours following immunization. Iliac, cervical lymph nodes
and spleen were individually harvested from each mouse. Single-
cell suspensions from cervical, iliac lymph nodes and spleens were
obtained as previously described [29].
In other experiments, purified anti-CD62L (MEL-14, Southern
Biotechnology, USA) was administered intravenously at 100 mg/
mouse 6 h after immunization with OVA plus CpG ODN1826
and then every 24 h until harvest. Fifty-seven hours after
immunization, lymph nodes and spleens were collected and
analysed by flow cytometry.
Flow cytometric analysis
Cell suspensions from lymph nodes and spleens were incubated
with Fc-blocking solution [0.5 mg CD16/CD32 mAb (clone 93)
(eBioscience, USA), 5% mouse serum, 5% rat serum, 0.2% sodium
azide (all from Sigma-Aldrich) in 100 ml of HBSS] for 30 min at
4uC. T cells were stained with PerCP-conjugated anti-mouse CD4
(clone RM 4-5) (BD Pharmingen), APC-conjugated anti-mouse
CD44 (clone IM7), CD45RB (clone C363.16A) or CD62L (Ly-22)
(clone MEL-14) (all from eBioscience) for 30 min at 4uC.
For DCs studies, cells were labelled with eFluor 710-conjugated
I-A/I-E (clone M5/114.15.2) and anti-mouse CD11c PE-conju-
gated (clone N418) (all from eBioscience).
CountBright absolute counting beads (Invitrogen, Molecular
Probes, Oregon, USA) were used for counting the number of
lymphocytes in each sample. All samples were analyzed by flow
cytometry (FACScalibur, Becton Dickinson, San Diego, CA). Data
analysis was performed by using Flow Jo software (Tree Star,
Ashland, OR, USA).
Statistical analysis
The number of proliferating T cells in lymph nodes and spleen
was analysed individually and values were expressed as mean 6
standard error of the mean (SEM).
Statistical differences between the quantity of antigen-specific
transgenic T cells detected in lymphoid organs at different time
points were assessed using one-way analysis of variance (ANOVA)
and Tukey’s post test for multiple comparisons. Statistical
significance was defined as P,0.05. Graphpad 4.0 software was
used for analysis.
Mathematical model and assumptions
A multi-type Galton Watson (MGW) branching process was
used to model in vivo CFSE proliferation data. The key
assumptions featuring MGW models are: 1) each cell action is
independent from others; 2) each dividing cell generates its own
branching process; 3) the cell has no memory about previous time-
steps (Markovian process) [37,44,45].
During each time-step Dt, it is assumed that a single cell in
generation i, i= 0,…., p (where p is the highest number of cell
generation tracked by flow cytometry), can divide with probability
ci into two i+1 generation cells, rest in its generation i with
probability di, or die/migrate with probability ai. Of course, 2 out
of the 3 probability parameters can vary independently, e.g. di and
ci, being ai = 12di2ci. We assume that the process has distinct
probabilities for cells in generations 0, 1, 2 [36], while probabilities
for generations i.2 are assumed equal to those of generation i= 2.
The MGW process is then specified by i) the choice of the time-
step Dt, ii) the initial cell number in generation 0 and iii) the vector
of parameters that determine the probabilities for each cell
generation, i.e., u = [d0, c0, d1, c1, d2, c2]
T. For this process, we
can define the first and second order moments, i.e. the mean and
covariance matrix of live cells counts at each time-point t, which in
turn, can be exploited to compute the Maximum Likelihood
function for the estimation problem of the parameter u [39].
However, in vivo experiments shown at least two factors which
violate the classical hypothesis on MGW models and the related
inferences from experimental data, requiring specific modeling
interventions. We outline below these items and the actions taken
to overcome them:
1) The draining site is not ‘isolated’ with respect to other lymph
nodes. This means that the cell proliferation process may be
seriously affected by migration from and to other distal lymph
nodes. In this case, the process division, death and quiescence
rates are biased, and it is not true anymore that their sum is 1.
2) All the in vivo experiments require animal sacrifice to collect
CFSE data. This means that measurements taken at different
time points actually refer to different individuals. This fact
introduces an inter-individual stochastic aspect which is not
considered in classical inference schemes.
With reference to the first issue, the impact of T-cell egress has
been ruled out, because the measurements, used for inference,
were carried out at early time points when most of primed T cells
have not left the draining lymph node. On the contrary, it is well
known that a significant entry phenomenon of naı¨ve T cells takes
place over the measurement time horizon, due to the recruitment
of T cells from other lymphoid sites. This problem has been solved
by using a 2 stage procedure. First, the pure MGW model (with
isolated draining lymph node) is exploited to compute the
probability parameters on an appropriate experiment, where
access is blocked through the treatment with the anti-CD62L
antibody (see section on Results). Second, the MGW model is
generalized by adding an immigration term r [46] to the naı¨ve T
cell population in the draining site. The generalized model can be
estimated by using the experimental data and exploiting the
MGW model used in the first stage.
Regarding the intrinsic difficulties of the second issue, model
identification has been performed by using relative frequencies as
model variables instead of cell counts. Relative frequency was
calculated as the percentage of OVA-specific CD4+ CFSE+ T cells
present in each generation towards the total number of OVA-
specific CD4+ T cells present in the lymph node. This choice
allowed us to derive an explicit expression for the Maximum
Likelihood function for the MGW model, since the distribution of
relative frequencies at different time points is asymptotically
normal, and the number of initial cells starting the proliferation
process is large [39]. In order to derive estimates uˆ and r
_
for the u
and r MGW model parameters, we constructed the following
iterative estimation procedure. We assume that an initial estimate
of the MGW model u = uˆ0 is available and proceed with the
following steps: i) compute the mean value of T-cell counts of the
MGW model for u = uˆ and relative frequencies in each generation
as a function of the parameter r; ii) estimate r
_
through a least
squares criterion using the measurements at t= 48 and t= 57; iii)
set r = r
_
and compute the first and second order moments of the
MGW with immigration terms; iv) update the estimate uˆ by
maximizing the new Maximum Likelihood Function of the relative
frequencies data. The estimation procedure is then repeated until
convergence of uˆ and r
_
.
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Results
Antigen-loaded DCs are localized in draining lymph
nodes
The localization of antigen-loaded DCs was assessed after
vaginal and nasal administration of the vaccine model formula-
tion. To this aim mice were inoculated vaginally or nasally with
OVA-Alexa Fluor 647 conjugate and the mucosal adjuvant CpG
ODN 1826. Mice were pre-treated with progesterone in order to
synchronize the estrous cycle to the diestrous phase and to
facilitate antigen-uptake. Antigen loading was analyzed following
vaginal or nasal immunization in draining lymph nodes (iliac and
cervical lymph nodes respectively), in distal lymph nodes (cervical
and iliac lymph nodes, respectively) and in the spleen. The
presence of antigen-loaded DCs in lymphoid sites was assessed 0,
12, 24 and 72 hours after the inoculum. Within the first day after
the immunization, antigen-loaded DCs (CD11c+ MHC class II+
cells) were localised only in the respective draining lymph nodes,
with about 6% and 4% of DCs detected following vaginal and
nasal immunization respectively (Fig. 1 A and B). On the contrary,
in distal lymph nodes and in the spleen, antigen-loaded DCs were
not detected at any time point (Fig. 1 A and B), indicating that also
following vaginal immunization antigen presentation occurs within
lymph nodes draining the immunization site, and not in other
lymphoid sites, in accordance with what was observed and
previously reported for nasal immunization [32]. No significant
differences in the number of antigen-loaded DCs were indeed
observed between vaginally and nasally immunized mice. These
data show that the antigen-uptake following vaginal immunization
of progesterone-treated mice was as efficient as the one observed
following nasal immunization.
Vaginal immunization elicits a rapid recruitment and
clonal expansion of CD4+ T cells in draining lymph nodes
To characterize T-cell clonal expansion and distribution, OVA-
specific transgenic CD4+ T cells, labeled with CFSE, were
adoptively transferred into recipient mice that were immunized
with the model formulation OVA and CpG ODN 1826 by the
vaginal or nasal route. The distribution of OVA-specific transgenic
T cells in adoptively transferred recipient mice was assessed in
draining and distal lymph nodes and spleen, 57 and 72 hours after
immunization and compared with the one detected at the time the
antigenic stimulus was given (time 0) [47] (Table 1). Following
vaginal immunization was observed a 5-fold increase of antigen-
specific CD4+ T cells in draining iliac lymph nodes at 57 hours
(Fig. 2 and Table 1), and a 7-fold increase at 72 hours (1610‘5
OVA-specific CD4+ T cells respect to 1.6610‘4 at time 0;
P,0.001; Table 1). The amount of total lymphocytes also
increased gradually from time 0 to 72 hours, suggesting a general
recruitment of lymphocytes from other lymphoid sites (Table 1).
On the contrary, in distal cervical lymph nodes, a 4 fold decrease
was detected at 57 hours (8.8610‘3 respect to 3610‘4 at time 0;
P,0.05; Table 1 and Fig. 2). The distribution of the antigen-
specific T cells described was comparable to the one observed
following nasal immunisation, where the recruitment of antigen-
specific T cells into draining sites appeared slower with a 3-fold
increase observed at 72 hours (8610‘4 respect to 3610‘4 at time
0; P,0.05; Table 1) while, a drastic reduction of antigen-specific
T-cell number was detected in distal iliac lymph nodes already
57 hours after immunization (1.7610‘3 respect to 1.5610‘4 at
time 0; P,0.001; Table 1 and Fig. 2). In the spleen, a 3-fold
decrease of antigen-specific T-cell was observed 57 hours follow-
ing both vaginal and nasal immunization (Fig. 2), probably due to
CD4+ T-cell recruitment in draining lymph nodes, while antigen-
specific T-cell numbers were reestablished at 72 hours (Table 1).
These data demonstrate a strong recruitment of antigen-specific T
cells into the lymph nodes draining the immunization site, that was
more rapid following vaginal than nasal immunization.
Fifty-seven hours following immunization of progesterone
treated mice, antigen-specific T cells initiated their clonal
expansion within draining lymph nodes, as identified by CFSE
dilution (Fig. 3). Five cell generations were detectable in iliac
lymph nodes of vaginally immunized mice and 4 major in cervical
lymph nodes of nasally immunized mice (Fig. 3). The presence of
an additional peak in vaginally immunized mice is consistent with
the observed more rapid T-cell recruitment. On the contrary, no
T-cell proliferation was observed in estrogen treated mice, since
antigen-uptake does not occur in the vaginal tissue in the estrous
phase, confirming the hormonal dependence of T-cell priming in
the genital tract [19]. Untreated animals maintained a high level of
CFSE fluorescence in lymph nodes, indicating that no cell division
occurred (Fig. 3).
CFSE proliferation data were analysed using
mathematical model based on Multy-type Galton Watson
branching process
A mathematical model based on the MGW branching process
with immigration was adopted to analyse antigen-specific CD4+
T-cell proliferation data in draining lymph nodes following vaginal
and nasal immunization. During each time-step it is assumed that
a single cell in generation i, can make three independent
probabilistic choices: divide with probability ci into two i+1
generation cells, rest in its generation i with probability di or die/
migrate with probability ai. A schematic representation of this
process is reported in Fig. 4A.
Since a lymph node is not an ‘isolated’ site but it is a component
of the complex immunologic network including different lymphoid
sites, T-cell proliferation process may be influenced by the
immigration from and the migration to distal lymph nodes with
a consequent bias on the division, death and quiescence rates. In
our case the migration component was excluded since measure-
ments were carried out at the time point (57 h) when most of
primed T cells have not left the draining lymph nodes. The
continuous recruitment of naı¨ve T cells into draining lymph nodes
from other lymphoid organs was considered by introducing an
‘immigration’ additive term in the MGW model, represented by a
parameter r, that indicates the number of naı¨ve T cells entering the
draining lymph node during each time step (immigration
parameter). We assumed as initial cell number, the amount of
antigen-specific T cells detected in a lymphoid organ at the time
when the antigenic stimulus was given [47]. The starting time
point for the counting process (n= 0) was fixed at t = 42 hours, the
time that is considered as the average time when a cell begins to
divide. The model time step was chosen as Dt = 3 hours based on
the assessment that three new cell generations were observed in
draining lymph nodes between 48 and 57 hours following vaginal
and nasal immunization (data not shown). Different probability
parameters were assumed for generations i= 0, 1 and 2 while
parameters for generations .2 were assumed equal to those for
i= 2 [36]. A Maximum Likelihood approach was adopted to
estimate model parameters including both the probability and the
immigration parameters. The parameters were estimated on the
number of OVA-specific CD4+ T cells in each cell generation,
reported as a relative frequency (percentage of CD4+ CFSE+ cells
per absolute number of lymphocytes/100). Data from a total of 20
animals immunized by the vaginal or nasal route and sacrificed at
time 0 or 57 were used for the model analysis. To improve the
estimate quality, an additional experiment was performed blocking
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T-cell entry into lymph nodes and providing data useful for an
initial evaluation of the probability parameters (uˆ0 in Material and
Methods Section). In this experiment, mice, previously adoptively
transferred with OVA-specific CD4+ T cells, were immunized
with OVA and CpG ODN and daily treated with anti-CD62L
antibody. As shown in Figure 4B, the anti-CD62L antibody
treatment prevented the entry of naı¨ve antigen-specific T cells
within the draining lymph nodes.
The estimated immigration parameter r
_
was 3280 following
vaginal immunisation and 915 following the nasal route. The
probability parameter vector u and the corresponding standard
deviations obtained from analyzing T-cell proliferation following
vaginal and nasal immunization are reported in Table 2. The
parameters were estimated for undivided cells (d0 and c0), first
generation (d1 and c1) and second and subsequent generations (d2
and c2). The values of parameters ci, representing the probability
of a cell to proliferate, calculated for i = 0, 1, 2 increased with
increasing number of cell generations and were higher following
vaginal than nasal immunisation. At the same time, the
parameters di, representing the probability of a cell to rest in the
same generation, were lower for vaginal than nasal immunisation.
These data suggest that after vaginal immunisation antigen-
specific T cells rapidly increase their ability to divide with
increasing number of cell divisions. Moreover, the parameters ai
for i = 0, 1, 2 (probability for a cell to die/migrate in each cell
division), calculates as ai = 12di2ci decreased with increasing
number of cell generations, suggesting a reduced probability to
die/migrate.
A snapshot of the experimental relative frequencies for each cell
generation and the relative frequencies predicted by the identified
model are reported in Figure 4C showing a satisfactory quality of
Figure 1. Antigen uptake by DCs following vaginal or nasal immunization. C57BL/6 mice were immunized by the vaginal or nasal route
with OVA Alexa Fluor 647-conjugate (25 mg/mouse) and CpG ODN (20 mg/mouse). Groups of animals were sacrificed 0, 12, 24 and 72 hours after
mucosal immunization and iliac lymph nodes (considered draining after vaginal and distal after nasal immunization respectively), cervical lymph
nodes (distal after vaginal and draining after nasal immunization respectively) and spleen were collected. DCs positive for fluorescent OVA were
analysed by flow cytometry. Shown is the percentage of OVA-Alexa Fluor 647 positive cells among total CD11c+ MHC class II+ cells.
doi:10.1371/journal.pone.0080545.g001
Figure 2. Antigen-specific T-cell distribution in draining, distal
lymph nodes and spleen following vaginal or nasal immuni-
zation. CFSE-labelled OT-II CD4+ T cells were transferred into recipient
C57BL/6J mice. Twenty-four hours later, recipient mice were immunized
with OVA (25 mg/mouse) and CpG ODN 1826 (20 mg/mouse) by the
vaginal or nasal route. The average number of OVA-specific CD4+ T cells
was calculated in draining, distal lymph nodes and spleen of mice
57 hours following vaginal or nasal immunization or in naı¨ve mice. Here
the ratio between the absolute number of OVA-specific CD4+ T cells
detected in lymphoid organs of mice immunized by the vaginal or nasal
route versus naı¨ve mice is reported.
doi:10.1371/journal.pone.0080545.g002
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fit represented by the low discrepancy between the model relative
frequencies and data.
In conclusion, the modeling analysis shows that the developed
model is reliable and can be fruitfully exploited for predictive
simulations and/or other possible purposes related to the study of
primary T-cell activation.
Antigen-specific transgenic T cells express activation and
homing molecules
The phenotype of transgenic CD4+ T cells was assessed in
draining lymph nodes three days following vaginal or nasal
immunization. The expression of surface markers, in immunized
or naı¨ve mice, was analysed in each generation (from 0 to 6)
identified by CFSE fluorescence intensity (Fig. 5A) and the
respective MFI values were reported in Fig. 5B. The modulation of
surface marker expression in transgenic CD4+ T cells was very
Table 1. Number of OVA-specific CD4+ T cells and total lymphocytes.
Route of immunization Lymphoid organa Time OVA-specific T cellsb Total Lymphocytes
Vaginal ILN 0 15.766.2 23036925
57 74.5634.5 438561300
72 106664***c 501762600
CLN 0 31.9621 426461322
57 8.863.6 * 389061190
72 1669.1 488862400
SPL 0 185.5624.5 40748611482
57 52.2619 *** 3005265117
72 157670 47902635887
Nasal CLN 0 31.9621 426461322
57 26628 483261219
72 79.5647.6 * 763663777
ILN 0 15.766.2 23036925
57 1.760.7 *** 19096541
72 4.563.2 *** 173561059
SPL 0 185.5624.5 40748611482
57 68.2616.4 * 47167610180
72 186.46118 43000615916
aILN: Iliac lymph nodes (subiliac, medial and external), CLN: cervical lymph nodes (superficial and posterior) and SPL: spleen.
bAbsolute number of OVA-specific CD4+ T cells calculated as [(percentage of CD4+CFSE+6absolute number of lymphocytes)/100] for each lymphoid organ. OVA-specific
T cells and total lymphocytes absolute numbers are to be multiplied610‘3.
cOne-way analysis of variance (ANOVA) and Tukey’s post test were used to compare the number of OVA-specific CD4+ T cells present in lymphoid organs at different
time points.
*P,0.05;
***P,0.001.
doi:10.1371/journal.pone.0080545.t001
Figure 3. Clonal expansion of OVA-specific CD4+ T cells following vaginal or nasal immunization. OVA-specific proliferation of CD4+ T
cells was assessed 57 hours following immunization in draining lymph nodes (iliac for vaginally and cervical for nasally immunized mice, respectively)
and analyzed as CFSE dilution (x axis) on the gated CFSE+ CD4+ populations with light scatter properties of lymphocytes. The number of respective
cell generation is reported for each peak. Results are representative of two experiments performed with six animals per group.
doi:10.1371/journal.pone.0080545.g003
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similar following vaginal and nasal immunization, with only small
differences in MFI values (Fig. 5A–B). Undivided antigen-specific
transgenic T cells (generation 0) still expressed high levels of the
naı¨ve CD45RB marker that was down-modulated in proliferating
T cells (Fig. 5A–B). The early activation marker CD69 was rapidly
up-regulated within the first cell cycle, with about a 10 fold
increase of the MFI compared to naı¨ve T cells, and then decreased
with advancing cycles of cell division (Fig. 5A–B). The expression
of the activation marker CD44 was increased gradually through-
out the cell generations maintaining a high level of expression in
the last generation observed (Fig. 5A–B). The expression of
CD62L was low in CD4+ T cells from naı¨ve mice, while it was up-
regulated in immunized mice with a fourfold increase in the most
advanced cell divisions (Fig. 5A–B).
The phenotypic analysis of antigen-specific proliferating CD4+
T cells confirmed that, following both vaginal and nasal
immunization, T cells were activated by the antigen encounter
and were able to acquire homing molecules to disseminate towards
distal lymphoid organs, as previously described following intrana-
sal immunization with a recombinant bacterial vector [29,31].
Antigen-specific CD4+ T cells disseminate to distal
lymphoid organs
OVA-specific CD4+ T-cell proliferation was analysed at
different time points (0, 2.5, 3, 5, and 7 days) following vaginal
or nasal immunization in the respective draining and distal lymph
nodes and spleen. The kinetic analysis of the T-cell priming
showed a rapid antigen-specific clonal division of transgenic CD4+
T cells in the respective draining lymph nodes already at day 2.5,
with about 75% of proliferating transgenic T cells in iliac and 60%
in cervical lymph nodes following vaginal or nasal immunization
respectively (Fig. 6). Proliferation values were almost steady
maintained at all analysed time points. The dissemination of
proliferated T cells into distal lymph nodes started at day 3 and
increased at day 5 with about 35% of vaginally primed T cells in
distal cervical lymph nodes and 50% of nasally primed T cells in
distal iliac lymph nodes (Fig. 6). The percentage of proliferated
cells in the spleen was about 50% and 75% of transgenic T cells
following vaginal and nasal immunization respectively (Fig. 6).
Seven days after immunization, divided T cells were still
detectable in distal lymph nodes and in the spleen. No significant
differences in the percentage of T-cell proliferation were observed
following vaginal and nasal immunization at any time-points
analysed in draining and distal lymph nodes and spleen.
Discussion
In the present work antigen-specific CD4+ T-cell primary
activation and dissemination following vaginal immunization was
characterized and compared to the one elicited by the nasal route.
The very early events of CD4+ T cell clonal expansion following
immunization by the two mucosal routes were analysed applying a
Multi-type Galton Watson branching process. Understanding in
depth the early events that lead to the immune response is crucial
for the rational development of appropriate prime-boost vaccine
strategies.
Following vaginal immunisation of mice treated with proges-
terone, antigen-bearing DCs were detected only in draining lymph
nodes and not in distal lymph nodes or in the spleen, in line with
what observed with nasal immunization [32]. In vaginally
immunized mice, antigen-loaded DCs persisted in draining lymph
nodes up to 72 hours while following nasal immunisation were
detected only within 24 hours. The extended persistence following
vaginal immunisation is probably due to the fact that mice were
Figure 4. A Galton Watson branching process in the discrete time. A) Schematic representation of the stochastic behavior of the branching
process. The i in the circle denotes the cell generation tracked with CFSE. Between two subsequent time-steps a single cell in i generation could take
independently by the other cells, three biological decisions: entering in division with probability ci and creating two cells of i+1 generation, resting
undivided in generation i with probability di, dying with probability ai = 12di2ci. The formalism allows us to calculate the moments of cell counts. B)
Proliferation of antigen-specific CD4+ T cells following treatment with isotype control or anti-CD62L antibody. Clonal division was assessed in draining
lymph nodes 57 hours following immunization and analyzed as CFSE dilution (x axis) on the gated CFSE+ CD4+ populations with light scatter
properties of lymphocytes. C) Comparison of the experimental relative frequencies obtained from 5 mice at the time-point t = 57 h and the predicted
values by the branching process for each cell generation following vaginal immunization.
doi:10.1371/journal.pone.0080545.g004
Table 2. MGW process parameter estimates.
Route Parameters Values Standard Deviation
Vaginal d0 0.38 0.03
c0 0.15 0.0483
d1 0.47 0.16
c1 0.26 0.124
d2 0.37 0.10
c2 0.50 0.126
Nasal d0 0.32 0.09
c0 0.11 0.0432
d1 0.40 0.13
c1 0.21 0.11
d2 0.55 0.18
c2 0.25 0.146
doi:10.1371/journal.pone.0080545.t002
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immunized in the diestrous phase, when the antigen uptake is
enhanced [17,19,48–50].
A recruitment of antigen-specific T cells from distal lymphoid
sites was observed in draining lymph nodes with a simultaneous
significant decrease of T cells in distal lymph nodes and in the
spleen. Vaginal immunization of mice was more effective at
stimulating antigen-specific CD4+ T-cell recall in draining lymph
nodes compared to nasal immunization. The analysis of T-cell
clonal expansion showed 5 cell generations, while at the same
time-point 4 cell generations were detected in cervical lymph
nodes following nasal immunization. These results are in line with
what reported by Marks and colleagues showing higher frequency
of antigen-specific T cells in draining iliac lymph nodes following
vaginal respect to nasal immunization with OVA and cholera
toxin [19]. This more rapid local T-cell proliferation following
vaginal immunization can be due to the lack of an organized
lymphoid tissue in the female genital tract. Indeed, upon vaginal
immunization, iliac lymph nodes directly drain the genital mucosa
[5], whereas following nasal vaccination antigen-specific T-cell
proliferation first takes place in the NALT and then in cervical
lymph nodes, as previously showed by our group and others
[30,51]. The T-cell proliferation observed following vaginal
immunization was strictly dependent on the estrous phase since
no T-cell response was observed in estrogen treated mice. This is
Figure 5. Phenotypic analysis of proliferating antigen-specific CD4+ T cells. The expression of CD45RB, CD69, CD44 and CD62L was
analysed as a function of cell divisions on OVA-specific CD4+ T cells from draining lymph nodes 72 hours following vaginal or nasal immunization
with OVA and CpG ODN 1826. A). Dot plot analysis of CFSE dilution (x axis) versus CD45RB, CD69, CD44 and CD62L expression (y axis) on OVA-specific
CD4+ T cells in naı¨ve and vaginally or nasally immunised mice. B). Mean fluorescence intensity of CD45RB, CD69, CD44 and CD62L expression per each
cell generation of OVA-specific CD4+ T cells from naı¨ve mice (open histogram) and vaginally or nasally immunised mice (dark and light gray
respectively). Cell divisions (from 0 to 6) are identified by CFSE intensity dilutions. Phenotypic analysis was performed on single mice. Results are
representative of two experiments with six animals per group.
doi:10.1371/journal.pone.0080545.g005
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in accordance with previous studies reporting that immune
response in the female genital tract depends upon the reproductive
hormones [3,18,22,52].
To characterize in depth the antigen-specific T-cell clonal
expansion in draining lymph nodes in the first hours following
antigen administration, a mathematical model, based on the
MGW branching process with immigration was exploited as a tool
to estimate in vivo the probability of an antigen-specific CD4+ T
cell to divide following the antigen-encounter. While this model
has been previously applied for in vitro studies [38–40], it had not
been previously applied to in vivo proliferation data. This is due to
the fact that in vivo analysis raises several difficulties, mainly due to
the fact that i) a lymph node is not an ‘isolated’ site but is part of a
complex system and ii) data are collected from different animals
introducing a inter-individual stochastic aspect. The impact of T-
cell egress has been ruled out by carrying out the measurements,
used for inference, at early time points (57 hours) when almost no
T-cell has left the draining lymph node. Nevertheless, a significant
recruitment of naı¨ve T cells from other lymphoid sites takes place
over the measurement time horizon. To address this problem, the
MGW model was generalized by adding an immigration term [46]
calculated with an appropriate experiment where access of naive T
cells was blocked through the treatment with the anti-CD62L
antibody. Concerning the second point, model identification has
been performed by using relative frequencies as variables instead
of cell counts. This choice allowed us to derive an explicit
expression for the Maximum Likelihood function for the MGW
model since the distribution of relative frequencies at different time
points is asymptotically normal, provided the number of initial
cells starting the proliferation process is large [39]. The good
quality of fit, represented by the low discrepancy between the
model relative frequencies and experimental data, shows that the
developed model is reliable and can be therefore fruitfully
exploited for predictive simulations and/or other possible purposes
related to the study of primary T-cell activation. Model parameter
estimates indicate that the probability of a cell to proliferate was
higher following vaginal than nasal immunization, suggesting that
the vaginal immunization route induces a higher CD4+ T-cell
proliferation in draining lymph nodes with respect to the nasal
route. Ongoing work is focused on modeling the whole complex
immunological network, including both draining, distal lymph
nodes and spleen, in order to get further quantitative information
and create a model capable of predicting the intensity and
distribution of T cells in the various lymphoid organs.
Proliferated antigen-specific CD4+ T cells were activated by the
antigen encounter, as shown by the rapid expression of the early
activation marker CD69 [53] and CD44 [54] within the very early
cell generations. On the contrary, CD45RB, a marker expressed
by naı¨ve T cells [55], was down-modulated as cell division
proceeded. The expression of CD62L, a molecule essential for
lymphocyte entry into lymph nodes [56], was gradually increased
by proliferated T cells. The phenotypic analysis of antigen-specific
proliferating CD4+ T cells in draining lymph nodes showed a
similar modulation pattern of surface marker following vaginal
and nasal immunization confirming that T cells were activated
and able to disseminate into distal lymph nodes. These findings are
in line with precedent data obtained following intranasal
immunization with recombinant bacteria [29,31]. Despite T-cell
recruitment and antigen-specific T-cell proliferation that was faster
in draining lymph nodes following vaginal immunisation, no
statistically significant differences in the percentage of antigen-
specific proliferated CD4+ T cells were observed at later time-
points (5 and 7 days) between vaginal and nasal immunization.
All together these data show that not only nasal but also vaginal
immunization, despite the absence of an organized mucosal
associated inductive site in the genital tract, is very efficient in
priming antigen-specific CD4+ T cells in draining lymph nodes
and inducing their dissemination from draining lymph nodes
towards distal lymphoid organs.
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